Answers are grounded in this paper and cite their sources.
Circular RNA (circRNA) is an emerging vaccine modality that is proposed to improve stability, reduce reactogenicity and extend antigen expression compared with linear mRNA. However, the relative contributions to vaccine performance of its covalently closed structure, its preparation quality and nucleotide modifications remain poorly described. Here, we systematically dissected these parameters in vivo across two antigen systems. We identified RNA preparation quality as a major contributor to markers of circRNA reactogenicity, with innate immune activation tracking with the abundance of residual low molecular weight RNA species in less refined preparations. High-quality circRNA exhibited markedly reduced innate immune activation compared with linear mRNA, independent of nucleotide modification. Despite these differences, circRNA and mRNA vaccines elicited comparable antibody titres and T cell responses, indicating that reduced innate activation did not translate into enhanced adaptive immune magnitude. Incorporating N 6 -methyladenosine (m 6 A) did not affect markers of reactogenicity or antigen expression but was associated with increased antibody avidity across both antigen systems, with neutralisation trending in the same direction. CircRNA vaccination also altered the anatomical distribution of germinal centre responses, reducing splenic antigen-specific germinal centre B cells at the measured timepoint while preserving lymph node responses. Together, these findings indicate that circRNA vaccine performance is shaped by RNA preparation quality and epitranscriptomic modification, rather than differences in innate immune activation.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: